N stage, a well‐established prognostic factor in lung cancer, and PD‐L1 expression, a reliable predictor of immunotherapy outcomes, emerged as critical factors impacting the prognosis of lung cancer patients undergoing immune combination therapy. The gene discussed is CD274; the disease is lung carcinoma.